Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 2
2011 2
2012 4
2013 1
2014 8
2015 13
2016 11
2017 11
2018 13
2019 10
2020 13
2021 19
2022 12
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
This trial is registered with ClinicalTrials.gov (NCT04423718) and is ongoing. FINDINGS: Of 1011 patients randomised to aflibercept 8q12 (n=336), 8q16 (n=338), or 2q8 (n=337) between Aug 11, 2020, and July 30, 2021, 1009 patients received study treatment (aflibercept …
This trial is registered with ClinicalTrials.gov (NCT04423718) and is ongoing. FINDINGS: Of 1011 patients randomised to aflibercept 8 …
Aflibercept, ipilimumab, and vemurafenib.
Hussar DA, Au AY. Hussar DA, et al. J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):291-4. doi: 10.1331/JAPhA.2012.12512. J Am Pharm Assoc (2003). 2012. PMID: 22370387 Review. No abstract available.
Influence of aflibercept on platelet activation profile.
Sobolewska B, Golenko J, Poeschel S, Grimmel C, Gatsiou A, Sopova K, Biedermann T, Schenke-Layland K, Stellos K, Ziemssen F. Sobolewska B, et al. Exp Eye Res. 2018 Oct;175:166-172. doi: 10.1016/j.exer.2018.06.009. Epub 2018 Jun 15. Exp Eye Res. 2018. PMID: 29908884
Interestingly, the expression of platelet-derived P-selectin and SDF-1 was not affected by aflibercept, except thrombin-activated CD62P with 0.04 mug/mL aflibercept (aflibercept vs. its solvent: MSI = 1.54, IC = 1.201-1.879 vs. MSI = 1.37, IC = 1.136-1.604 [P …
Interestingly, the expression of platelet-derived P-selectin and SDF-1 was not affected by aflibercept, except thrombin-activated CD6 …
Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper.
Avitabile T, Azzolini C, Bandello F, Boscia F, De Falco S, Fornasari D, Lanzetta P, Mastropasqua L, Midena E, Ricci F, Staurenghi G, Varano M. Avitabile T, et al. Eur J Ophthalmol. 2017 Nov 8;27(6):627-639. doi: 10.5301/ejo.5001053. Eur J Ophthalmol. 2017. PMID: 29077188 Review.
PURPOSE: To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review. ...CONCLUSIONS: Consensus was reached among experts on how to best treat patients with DME with aflibercept....
PURPOSE: To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review. . …
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion.
Cehofski LJ, Kruse A, Alsing AN, Sejergaard BF, Nielsen JE, Schlosser A, Sorensen GL, Grauslund J, Honoré B, Vorum H. Cehofski LJ, et al. Molecules. 2022 May 24;27(11):3360. doi: 10.3390/molecules27113360. Molecules. 2022. PMID: 35684299 Free PMC article.
Retinal proteome changes following aflibercept intervention in CRVO remain largely unstudied. Studying proteomic changes of aflibercept intervention may generate a better understanding of mechanisms of action and uncover aspects related to the safety profile. ...Pro …
Retinal proteome changes following aflibercept intervention in CRVO remain largely unstudied. Studying proteomic changes of aflibe …
Overcoming resistance to antiangiogenic therapies.
Tejpar S, Prenen H, Mazzone M. Tejpar S, et al. Oncologist. 2012;17(8):1039-50. doi: 10.1634/theoncologist.2012-0068. Epub 2012 Jul 6. Oncologist. 2012. PMID: 22773560 Free PMC article. Review.
Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
Kasi PM, Hubbard JM, Grothey A. Kasi PM, et al. Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):273-6. doi: 10.1586/17474124.2015.1001743. Epub 2015 Jan 12. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25579664 Review.
With the advent of biologics, the survival and quality of life of patients diagnosed with metastatic colorectal cancer (mCRC) has improved. These agents include anti-VEGF agents (bevacizumab/aflibercept), anti-EGFR antibodies (panitumumab/cetuximab) and regorafenib (an ora …
With the advent of biologics, the survival and quality of life of patients diagnosed with metastatic colorectal cancer (mCRC) has improved. …
Advances in pharmacotherapy for wet age-related macular degeneration.
Santarelli M, Diplotti L, Samassa F, Veritti D, Kuppermann BD, Lanzetta P. Santarelli M, et al. Expert Opin Pharmacother. 2015;16(12):1769-81. doi: 10.1517/14656566.2015.1067679. Epub 2015 Jul 13. Expert Opin Pharmacother. 2015. PMID: 26165696 Review.
Besides the development of new drugs, a better characterization of patients is also needed, taking into account variables such as choroidal neovascularization subtypes and genetic factors, in order to identify a tailored treatment for each patient....
Besides the development of new drugs, a better characterization of patients is also needed, taking into account variables such as choroidal …
Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P. Riondino S, et al. Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605. Cardiovasc Hematol Agents Med Chem. 2017. PMID: 28137223 Review.
The picture is further complicated by the understanding that the amount of VEGF production is influenced by genetic factors, with environmental ones accounting only for 20-30% of its variations. This has recently prompted the design of various pharmacogenetic studies to in …
The picture is further complicated by the understanding that the amount of VEGF production is influenced by genetic factors, with env …
116 results